Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population.
The rising incidence of multi-drug resistant (MDR) gram-negative infections in the intensive care unit (ICU) continues to challenge clinicians and has resulted in reemergence of the glycopeptide antibiotic colistin. Over the past 11 years, 14 patients at a tertiary pediatric burn center were treated with colistin for gram-negative infections resistant to all tested antibiotics. This study reviews the safety of such treatment and the outcome for this cohort of patients. All hospitalized patients treated with intravenous colistin between 1990 and 2005 were identified. A retrospective chart review was performed for each patient. Demographic data, along with information regarding the type and severity of injury, were collected. Data with respect to microbiology, renal status, and neurological events were also noted. Over an 11-year period, we identified 14 children infected with pan-resistant gram-negative organisms requiring 16 courses of colistin. Two children (14.3%) developed significant rises in serum creatinine concentration; however, no child required renal replacement therapy or developed neurologic complications attributable to colistin. Favorable response rate was 78.6% (11/14), and overall mortality was 14.3% (2/14); both deaths were attributed to sepsis. In our experience with 14 children treated with intravenous colistin, two developed a significant elevation in serum creatinine concentration during the course of therapy and neurotoxicity was not reported. Colistin should be dispensed with great caution, but it appears to have an acceptable safety profile in children and may be used in select cases of infection with highly resistant gram-negative organisms.
Goverman
Jeremy
J
Burns Service, Bigelow 13, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Weber
Joan M
JM
Keaney
Timothy J
TJ
Sheridan
Robert L
RL
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002056:Burns / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D003091:Colistin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003404:Creatinine; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D006801:Humans; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D008297:Male; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D003404:Creatinine; D003091:Colistin